CKD 512
Alternative Names: CKD-512Latest Information Update: 30 Jun 2023
At a glance
- Originator Chong Kun Dang
- Class Antineoplastics
- Mechanism of Action Adenosine A2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 19 Apr 2023 Preclinical trials in Cancer in South Korea (unspecified route), prior to April 2023 (Chong Kun Dang Pharmaceuticals pipeline, April 2023)